This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Should You Buy Melco Resorts (MLCO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MLCOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
by Moumi Mondal
HOLX's Molecular Diagnostics growth stays resilient, as new assays and test adoption offset funding headwinds.
ABTNegative Net Change RHHBYPositive Net Change HOLXPositive Net Change
medical medical-devices
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
by Zacks Equity Research
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
DGXPositive Net Change CAHPositive Net Change CORPositive Net Change PAHCPositive Net Change
medical medical-devices
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes
by Zacks Equity Research
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
ALGNPositive Net Change COOPositive Net Change CORPositive Net Change ITGRPositive Net Change
medical medical-devices
Analog Devices (ADI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ADIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Affiliated Managers Group (AMG) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?
by Zacks Equity Research
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
BSXPositive Net Change CAHPositive Net Change CORPositive Net Change PAHCPositive Net Change
medical medical-devices
Can ISRG Maintain Robotics Edge Amid Rising Rivalry & Budget Strain?
by Indrajit Bandyopadhyay
ISRG posted strong Q1 growth, but rising rivals and tighter hospital budgets test its robotics dominance and pricing power.
MDTPositive Net Change ISRGPositive Net Change GMEDPositive Net Change
medical medical-devices
Best Value Stocks to Buy for July 1st
by Zacks Equity Research
MITSY, NGD and PDEX made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 1, 2025.
MITSYNegative Net Change NGDPositive Net Change PDEXPositive Net Change
medical-devices
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
UNHNegative Net Change NVOPositive Net Change LLYPositive Net Change CVSNegative Net Change ELVNegative Net Change
medical medical-devices
Hims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?
by Debanjana Dey
HIMS and LFMD are surging in the telehealth race, but which one has stronger earnings growth and expansion momentum? Let's see.
HIMSPositive Net Change LFMDNegative Net Change
medical medical-devices
Should You Buy Digi Power X Inc. (DGXX) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DGXXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Lumentum (LITE) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LITEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
by Zacks Equity Research
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
BSXPositive Net Change TECHPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
by Zacks Equity Research
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
SYKNegative Net Change CORPositive Net Change ITGRPositive Net Change HIMSPositive Net Change
medical medical-devices
Grupo Televisa (TV)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
TVPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy TSMC (TSM) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TSMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Shoals Technologies Group (SHLS) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SHLSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OneSpaWorld (OSW) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OSWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
by Moumi Mondal
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
AZNPositive Net Change ICLRNegative Net Change IQVPositive Net Change TEMPositive Net Change
medical medical-devices
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
by Zacks Equity Research
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
ANGOPositive Net Change SNNPositive Net Change CVSNegative Net Change ITGRPositive Net Change
medical medical-devices
Walgreens Q3 Earnings Top Estimates, Stock Up, Gross Margin Declines
by Zacks Equity Research
WBA tops Q3 earnings and sales estimates and lifts shares, but the gross margin contracts, and guidance is withdrawn.
ISRGPositive Net Change VEEVPositive Net Change ITGRPositive Net Change
earnings medical medical-devices
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
by Indrajit Bandyopadhyay
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
HSTMNegative Net Change AMWLNegative Net Change DOCSNegative Net Change
medical medical-devices
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
by Zacks Equity Research
West Pharmaceutical Services rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
ALGNPositive Net Change CAHPositive Net Change MCKPositive Net Change WSTPositive Net Change
medical medical-devices
Is the Options Market Predicting a Spike in Brainsway Stock?
by Zacks Equity Research
Investors need to pay close attention to Brainsway stock based on the movements in the options market lately.
BWAYPositive Net Change
medical medical-devices